华熙生物科技股份有限公司2025年年度业绩预增公告

Core Viewpoint - The company anticipates a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of between RMB 270 million and RMB 320 million, representing a year-on-year increase of 54.93% to 83.63% [2] Performance Forecast - The expected net profit attributable to shareholders for 2025 is between RMB 270 million and RMB 320 million, an increase of RMB 95.73 million to RMB 145.73 million compared to the previous year [2] - The projected net profit, excluding non-recurring gains and losses, is between RMB 167 million and RMB 217 million, reflecting an increase of RMB 59.73 million to RMB 109.73 million year-on-year [2] Previous Year Performance - In the previous year, the total profit was RMB 213.39 million, with a net profit attributable to shareholders of RMB 174.27 million, and a net profit excluding non-recurring gains and losses of RMB 107.27 million [2] Reasons for Performance Changes - The company is focusing on "agile management and growth efficiency," optimizing its organizational structure and operational model, which is expected to enhance operational efficiency and reduce costs, leading to a projected net profit increase of 54.93% to 83.63% [2][3] - Management expenses are expected to decrease by over 10% year-on-year due to effective cost control [3] - Sales expenses are projected to decline by over 30% year-on-year, contributing to improved profitability despite revenue pressures [3] Research and Innovation - The company is advancing research in key areas such as glycoscience and cell biology, focusing on the regulation mechanisms of extracellular matrix and aging intervention [3] - The integration of AI technology into business processes is expected to enhance operational efficiency across production, supply chain, and management [3] Future Outlook - The company will continue to prioritize technological innovation to strengthen its long-term competitive advantage and improve operational quality and sustainable development [4]